US Patent

US7897792 — Coumarin derivative having antitumor activity

Composition of Matter · Assigned to Chugai Pharmaceutical Co Ltd · Expires 2027-02-09 · 1y remaining

Vulnerability score 35/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a compound represented by general formula (1) or a pharmaceutically acceptable salt thereof, which has antitumor activity.

USPTO Abstract

The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y 1 and Y 2 are selected from —N═ etc., Y 3 and Y 4 are selected from —CH═ etc., A is selected from sulfamide etc., R 1 is selected from hydrogen etc., and R 2 is selected from C 1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

Drugs covered by this patent

Patent Metadata

Patent number
US7897792
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-02-09
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Chugai Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.